bcl11a sickle cell disease

BCL11A represents a promising target in sickle cell disease because of its regulation of the fetal-adult hemoglobin switch at the gamma-globin locus, investigators said in their late-breaking study abstract. Dr. Esrick described BCH-BB694, a lentiviral vector encoding a BCL11A-targeting small hairpin RNA embedded in a microRNA scaffold (shmiR). As of data presentation, 8 patients were enrolled in the trial. In a 3-patient study presented at ASH, investigators believe they have found a therapeutic target to cure sickle cell disease. Most patients had genotype HbSS disease and participant ages ranged from 7 to 36. “CL11A protein levels evaluated by immunoblot in subject BCL002 at 30 days (PB) and 6 months (BM) post-infusion showed highly effective and selective knockdown of BCL11A in erythroid progenitors with no reduction in BCL11A expression in B lymphoid cells,” the authors wrote. Total fetal hemoglobin has increased and remained stable at between 23% and 43% for the five patients, who are producing “stably high” average amounts of fetal hemoglobin per F cell, at 10 to 16 picograms of fetal hemoglobin per cell, while 37% to 62% of the F cells’ total hemoglobin is fetal hemoglobin, she added. Also, no patient required transfusions, except in one patient with severe underlying neurovascular disease who was planned to continue transfusions after gene therapy. See our Other Publications. Copyright  © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA. There may soon be a cure for sickle cell disease. is a consultant to Adventrx Corporation and has received an honorarium and travel expenses from Adventrx Corporation for assisting them with a possible clinical trial of an agent to treat vasooclusive crisis in sickle cell disease. This level is believed to prevent sickling under physiological oxygen saturation. The increase in HbF translated to improvement in severity of SCD, she noted. BCL11A regulates the fetal-adult hemoglobin switch by repressing expression at gamma (y)-globin locus, representing a potential therapeutic target for sickle cell. The information provided is for educational purposes only. Validation of BCL11A as therapeutic target in sickle cell disease: results from the adult cohort of a pilot/feasibility gene therapy trial inducing sustained expression of fetal hemoglobin using post-transcriptional gene silencing. “At the 3-month time point before re-starting transfusions, the subject with moyamoya had a pre-transfusion Hb of 11 g/dL with 76% of non-transfused cells containing on average 17pg F/F cell,” the authors wrote. ASH 2019. They did not find any grade 3 or 4 adverse events linked with mobilization, collection, or infusion. Leukemia, Myelodysplasia, Transplantation, ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD, Clinical Advances in Thrombocytopenia Series, Second-Line Non-Small Cell Lung Cancer: Follow-Up Survival Data with Immunotherapy, Nurse Practitioners / Physician Assistants. In a press briefing at ASH on the late-breaking trials, David Williams, MD, Boston Children’s Hospital, explained how this trial shows promise in curing sickle cell disease. Ultimately, the study points to a potential cure for sickle cell. “For all subjects, we estimated the fraction of RBCs containing significant Hb sickle polymers and the amount of polymer in each sickled RBC at physiologic oxygen tension (where 50% of monomeric hemoglobin was oxygen saturated, or the P50).”. Among 4 patients who had been followed for at least 3 months after gene therapy infusion, Hb returned to “near-normal” levels (range = 10.9-11.8 g/dL) and had substantially increased compared with baseline Hb levels. The modified cells were then infused into patients. SOURCE: Esrick EB et al. No patients have required transfusion, except one with severe underlying vascular disease for whom post–gene therapy transfusions were planned, she said. Abstract #LBA-5. There also were not any adverse events related to the gene therapy product and vector copy number was stable in bone marrow (BM) and peripheral blood (PB) in all cell lineages during the length of the study, with the latest time point studies at 15 months and ranged from .45-2.85 copies per cell in erythroid progenitor cells. Copyright © 2020 by American Society of Hematology, Focus on Classical Hematology (Volume 6, Issue 12.1). For the patient who required transfusion, gene therapy allowed clinicians to extend his transfusion interval from 1 to 2 months, while still maintaining a pre-transfusion sickle Hb level no higher than the level prior to infusion, Dr. Esrick added. Unauthorized use prohibited. The calculated average HbF per F cell was greater than 10 pg in all subjects and a quantitative single cell HbF flow analysis showed the majority of F cells had greater than 4 pg F/cell. BCL11A regulates the fetal-adult hemoglobin switch by repressing expression at gamma (y)-globin locus, representing a potential therapeutic target for sickle cell. Addition of Elotuzumab Prolongs Survival in Relapsed or Refractory Myeloma, Fresh Frozen Plasma May Help Maintain Successful Pregnancy in Women With Congenital TTP, Smokeless Tobacco Linked to Subtherapeutic INR in Warfarin-Treated Patient, Evaluating the TP53 State and Its Implications for Myelodysplastic Syndromes Outcomes, MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors, Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL, Editor’s Corner: Move Over Millennials: Time to Teach Outside the Boundaries. Dr. Esrick described BCH-BB694, a lentiviral vector encoding a BCL11A-targeting small hairpin RNA embedded in a microRNA scaffold (shmiR). The single-center pilot and feasibility study, originally designed to include a total of seven patients, now has an expanded enrollment goal of 15 patients, and a multicenter phase 2/3 study is planned that will enroll a larger group of patients with sickle cell disease, according to Dr. Esrick. A BCL11A-targeting gene therapy in patients with sickle cell disease (SCD) led to higher levels of fetal hemoglobin (HbF) and reductions in the severity of disease… This issue dives into the FDA's expedited review pathways, the progress and setbacks in gene therapy for hemophilia, and more. Following infusion of modified cells, the vector copy number was found to be stable at 6 months, indicating effective knockdown of BCL11A at the protein level. Now, new research led by Howard Hughes Medical Institute (HHMI) investigator Stuart H. Orkin of Children’s Hospital Boston, Dana Farber Cancer Institute, and Harvard Medical School shows that silencing a protein known as BCL11A can reactivate fetal hemoglobin production in adult mice and effectively reverses sickle cell disease. ORLANDO – A gene therapy approach that targets a major repressor of fetal hemoglobin appears to be acceptably safe and to mitigate the pathology of sickle cell disease among the five patients infused so far, an investigator reported at the annual meeting of the American Society of Hematology. Esrick EB, Achebe M, Armant M, et al. BCL11A represents a promising target in sickle cell disease because of its regulation of the fetal-adult hemoglobin switch at the gamma-globin locus, investigators said in their late-breaking study abstract. Saving You Time. The results of the pilot study of the shmiR vector approach, although preliminary and in need of longer follow-up, contribute to a larger body of research showing that multiple gene therapy approaches hold promise in this disease, said Robert Brodsky, MD, professor of medicine and director of the division of hematology at Johns Hopkins School of Medicine, Baltimore. Validated assays at the single-cell level are needed to better understand the effect of this gene therapy and eventually compare it to other therapeutic approaches in sickle cell disease, according to Dr. Esrick. A BCL11A-targeting gene therapy in patients with sickle cell disease (SCD) led to higher levels of fetal hemoglobin (HbF) and reductions in the severity of disease, according to findings from a small pilot study. “In our treated patients, we’ve seen a consistent and substantial induction in fetal hemoglobin,” Dr. Esrick said, noting that the longest follow-up to date for the five treated patients is now 18 months. The patients, who range in age from 12 to 26 years, are producing and maintaining very high numbers of F cells, or erythrocytes with measurable fetal hemoglobin, she said. Conference | American Society of Hematology. Contact Us | Terms of Service | Privacy Policy. “We’re collaborating with several colleagues on exploratory assays to accomplish this,” she said, adding that the work is ongoing. BCL11A regulates the fetal-adult hemoglobin switch by repressing expression at the gamma (γ)-globin locus (Sankaran et al., Science, 2008), and thus it represents an appealing therapeutic target for sickle cell disease (SCD).BCH-BB694 is a lentiviral vector (LVV) encoding a shRNA targeting BCL11A embedded in a microRNA scaffold (shmiR) allowing erythroid-specific knockdown to induce γ … They also plan to conduct the next phase 2 or 3 study at multiple sites. Use of this Web site is subject to the medical disclaimer. The patients are currently 7, 9, and 17 months post infusion. Dr. Esrick reported having no disclosures. Cell products were manufactured for 6 patients, Dr. Esrick reported, with cell doses of 3.3 to 8.3 million CD34-positive cells/kg and high vector copy numbers, “indicating successful manufacturing and a highly efficient vector.”. The approved open-label study was not randomized and held at a single center, where 3 adult patients were enrolled with more than 6 months of follow up. All rights reserved. “The transcription factor BCL11A is a strong repressor of gamma-globin, making it an appealing target for fetal hemoglobin induction.”. “The exciting thing is that there are now multiple ways of going at this previously incurable disease,” Dr. Brodsky, who was not involved in the research, said during a press conference. All rights reserved. “In conclusion, these data demonstrate successful and sustained engraftment in three adult patients treated with LVV-delivered shmiR technology targeting BCL11A.”. BCH-BB694 is an investigational gene therapy product manufactured by embedding a BCL11A-targeting structure in patients’ autologous CD34-positive cells using a shmiR lentiviral vector. All rights reserved. See more with MDedge! Knocking down BCL11A using a lentiviral vector-based approach resulted in effective induction of fetal hemoglobin and significant attenuation of the sickling phenotype, with no vector-related adverse events, investigator Erica B. Esrick, MD, of Children’s Hospital Boston, said during the meeting’s late-breaking abstracts session. All 3 of the adult subjects, which were between 21-26 years old, demonstrated neutrophil engraftment on day +22 with adverse events consistent with busulfan conditioning. Following gene therapy, treated patients have had no instances of vaso-occlusive pain crises, respiratory events, or neurologic events. In addition, there were no AEs related to the medicinal product. Autologous CD34+ cells were collected by plerixafor mobilization and then transduced ex vivo with the BCH-BB694 shmiR lentiviral vector. Rather than interfering with BCL11A, these approaches are introducing genes that encode fetal hemoglobin itself or a corrected beta hemoglobin that doesn’t sickle. After testing and releasing the gene modified cells, the investigators infused them into the patients, who had received busulfan conditioning. Presented at the 2019 ASH Annual Meeting, December 10, 2019; Orlando, FL. “Fetal hemoglobin prevents the polymerization of sickle hemoglobin [and] pancellular distribution of fetal hemoglobin is a therapeutic goal because it protects a large proportion of cells from sickling,” Dr. Esrick explained.

Studio 54 Moon Spoon, Lucky Day Company, Bling Effect Tiktok, Mazda 6 Body Kit, Two Heads One Heart Meaning, Amy Abbott Alaska, Garden Of Salvation Chest Glitch Patched, Easter Egger Chickens Start Laying, 1990 Ohio State Football Roster, Gntm Greece 2020, Boston Whaler Steering Console, Nate Mendel Parents, Space Hunter Game, Nfl Network Kay Adams, Baby Eslabon Armado Lyrics English Translation, How To Clear A Vin Locked Bully Dog Power Pup, Drs Rules For Lbw, Susan Kare Net Worth, Lil Durk 2020, Fitness Reality 810xlt Lat Pulldown, Ukrainian Alphabet Cursive, Keese Wings Botw, Licking County Auditor Property Search, Quarry Rimworld Mod, Ashlesha Nakshatra 2020 Predictions, Edgar Allan Poe Argumentative Essay, Lacandon Jungle Map, How Old Is Omoni Oboli Son's, Is Gogoanime Legal, Nombres Antiguos De Mujer Bonitos, How To Get Grey Warwick, Shotgun Proof Marks Steel Shot, Which Zodiac Sign Hates Each Other, Who Is Bobby Humphreys Ex Wife, Honda Atc For Sale Craigslist, Bosch 1590evs Problems, Paul Krasinski Height, Alexander Dobrev Wikipedia, Baseball Heroes Masters Game Online, 38 Special Remanufactured Ammo, Exo Members Left, Ls2 Valiant Vs Shark Evo One 2, Dogs For Sale In Holland Mi, Hey Hey Meaning In Texting, Adventures Of Mana Walkthrough, Cadence Of Hyrule Map Icons, Pelican Kayak Reviews, Memorable Holiday Essay, List Of Weird Sexualities, Tamara Smart Net Worth, Pros And Cons Of Peaceful Protest, 338 Federal Vs 338 Win Mag, Ring Of The Gods Osrs Ge, Sloane Skipper Reddit, Uwe Baltner Net Worth, All Alone Memes, Craigslist Ohio Pets, Seven Seconds Why Didn't Jablonski Tell The Truth, Mbti Mental Illness, Juan Igor González Net Worth, Panda Helper Fix, I Need U Piano Sheet, Getting Rid Of Oak Trees, Real Life Examples Of Mass, Persona 5 Calendar, New Races Skyrim Se, Alolan Muk Weakness, Jamie Mclennan Parents, Animal House Full Movie Reddit, Calypso Drink Sam's Club, Junior Rugby League Fixtures 2020, Anthony Davis Marlen P Instagram, 24 Hour Autozone Near Me, Uwe Baltner Net Worth, Martin Cummins Wife,